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ABSTRACT Leishmania major is the causative agent of cutaneous leishmaniasis (CL).
No human vaccine is available for CL, and current drug regimens present several
drawbacks, such as emerging resistance, severe toxicity, medium effectiveness,
and/or high cost. Thus, the need for better treatment options against CL is a priority. In the present study, we validate the enzyme methionine aminopeptidase 1 of L.
major (MetAP1Lm), a metalloprotease that catalyzes the removal of N-terminal methionine from peptides and proteins, as a chemotherapeutic target against CL infection. The in vitro antileishmanial activities of eight novel MetAP1 inhibitors (OJT001
to OJT008) were investigated. Three compounds, OJT006, OJT007, and OJT008, demonstrated potent antiproliferative effects in macrophages infected with L. major
amastigotes and promastigotes at submicromolar concentrations, with no cytotoxicity against host cells. Importantly, the leishmanicidal effect in transgenic L. major
promastigotes overexpressing MetAP1Lm was diminished by almost 10-fold in comparison to the effect in wild-type promastigotes. Furthermore, the in vivo activities of
OJT006, OJT007, and OJT008 were investigated in L. major-infected BALB/c mice. In
comparison to the footpad parasite load in the control group, OJT008 decreased the
footpad parasite load signiﬁcantly, by 86%, and exhibited no toxicity in treated mice.
We propose MetAP1 inhibitor OJT008 as a potential chemotherapeutic candidate
against CL infection caused by L. major infection.
KEYWORDS Leishmania major, antiparasitic agents, cutaneous leishmaniasis, drug
discovery, methionine aminopeptidase 1, molecular parasitology, murine model of
cutaneous leishmaniasis, parasitology, target validation

T

he leishmaniases are a complex of infectious diseases caused by more than 20
kinetoplastid protozoan parasites that belong to the Trypanosomatidae family and
genus Leishmania. Roughly 12 million people are infected, with an increasing incidence
of 2 million per year (1). Moreover, approximately 350 million people are at risk of
contracting leishmaniasis in 98 countries across ﬁve continents, and it is included in the
neglected tropical diseases (NTD) group (1). Clinical manifestations range from nodular
and ulcerative skin lesions to progressive mucocutaneous and visceral forms. Cutaneous leishmaniasis (CL) is the predominant human clinical manifestation, and it is
characterized by particular localized skin ulcers (2, 3). CL is considered a tropical disease.
In the Old World, CL is mainly caused by Leishmania aethiopica, Leishmania tropica, and
Leishmania major, affecting the Middle East, Mediterranean littoral, Arabian Peninsula,
Africa, Near Asia, Indian Subcontinent, and other areas (4, 5). In the New World, CL is
caused by several species, such as Leishmania mexicana, Leishmania amazonensis,
Leishmania venezuelensis, or members of the subgenus Vianna, which includes LeishJune 2020 Volume 64 Issue 6 e01422-19
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mania Vianna braziliensis, L. (V.) guyanensis, L. (V.) panamensis, and L. (V.) peruviana (6).
Nonetheless, with increases in travel, military activities, and migration, the disease
presents a risk for populations that were previously unaffected, including in the United
States, where CL is nowadays considered an emerging concern (7–10).
Currently, there are no available vaccines against leishmaniasis (11, 12), and therefore, therapies rely solely upon a reduced number of drugs (13). These drugs, such as
the pentavalent antimonials meglumine antimonate and sodium stibogluconate (Glucantime and Pentostam, respectively), miltefosine (Impavido), and liposomal amphotericin B (AmBisome), pose several challenges because of their numerous toxic side
effects, high cost, and parenteral administration and the potential emergence of
chemoresistant parasites (14). Hence, there is an urgent need for the development of
less toxic, more cost-effective, and more therapeutic interventions against leishmaniasis.
Essential enzymes like methionine aminopeptidase (MetAP) have been suggested as
promising targets for the development of novel antiparasitic agents. Methionine
aminopeptidases are classiﬁed into two different types, MetAP1 and MetAP2. The latter
contains a 60-amino-acid insertion that distinguishes it from MetAP1 (15, 16). MetAP1
is a dinuclear metalloprotease that catalyzes the removal of N-terminal methionine
residues from peptides and proteins (17). MetAP1 proteins bind to metal ions like
cobalt or zinc for their activity (18), and disruption of MetAP1 impairs proper protein
folding, posttranslational modiﬁcations, biologic maturation, and translocation of some
newly synthesized peptides and proteins within the cell (19). The functionality and
importance of MetAP1 has been shown in several organisms, including Escherichia coli,
Salmonella enterica serovar Typhimurium, and Mycobacterium tuberculosis, where the
knockdown of the MetAP1 gene leads to lethal effects or reduced viability (20–22). In
Saccharomyces cerevisiae, the knockdown of MetAP1 leads to slow growth, while the
knockdown of MetAP1 and MetAP2 leads to nonviable yeast strains (23). Furthermore,
studies have been made of MetAP1b in the protozoan Plasmodium falciparum
(PfMetAP1b), one of four types of MetAP found in P. falciparum. The observation of
antiproliferation effects on several P. falciparum strains by highly selective inhibitors of
PfMetAP1b has led to the discovery of selective MetAP inhibitors (15). Moreover, MetAP
inhibitors have shown promising results against tuberculosis, fungal infections, rheumatic disease, various forms of cancer, malaria, leishmaniasis, and other diseases (15,
22–30). Unlike the protozoan P. falciparum, only one methionine aminopeptidase has
been discovered in L. major (MetAP1Lm), which has a 50% sequence similarity with
human MetAP1 (MetAP1 of Homo sapiens [HsMetAP1]) and less than 14% similarity to
human MetAP2 (HsMetAP2) (Fig. S1 in the supplemental material). Another report
highlighted the potential role of type 2 MetAP in Leishmania donovani (31), and a
recent study reported the expression, puriﬁcation, and characterization of MetAP1 in L.
donovani, giving more evidence of MetAP1 as a drug target for Leishmania spp. (32).
Therefore, we selected methionine aminopeptidase 1 (MetAP1) as a prospective chemotherapeutic target.
Using an integrated whole-cell-based screening and chemogenetic approach, we
systematically identiﬁed and characterized three novel MetAP1Lm inhibitors. Previously,
a high-throughput screen consisting of a library of 175,000 structurally diverse small
molecules was conducted by Olaleye et al. (22). Their study successfully identiﬁed lead
MetAP1 inhibitors against M. tuberculosis (22). As part of the drive to ﬁnd new
antileishmanial treatments, we screened and characterized the antiparasitic activity of
these novel MetAP1 inhibitors against CL infection caused by L. major in vitro and in an
in vivo model. MetAP1Lm inhibitors OJT006, OJT007, and OJT008 showed potent
leishmanicidal activity and remarkable selectivity indexes in vitro. More importantly,
OJT008 signiﬁcantly reduced the parasitic load with no evident toxicity in a preclinical
in vivo model. These ﬁndings suggest MetAP1Lm as a potential therapeutic target for
the development of efﬁcient and nontoxic drugs against CL. MetAP1 can serve as a
potential target for the development of novel anti-infective agents to combat the
emergence of drug-resistant pathogens.
June 2020 Volume 64 Issue 6 e01422-19
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TABLE 1 Antiparasitic activities of OJT compounds at 72 h in L. major promastigotes and
cytotoxicities of the compounds to intraperitoneal mouse macrophages
Value ⴞ estimated interval for:
Compound
OJT001
OJT002
OJT003
OJT004
OJT005
OJT006
OJT007
OJT008

EC50 (M)a
10.9 ⫾ 1.3
11.96 ⫾ 0.84
14.36 ⫾ 0.45
3.36 ⫾ 0.13
6.8 ⫾ 0.57
⬃0.6
0.38 ⫾ 0.006
⬃0.24

CC50 (M)b
NAd
NA
NA
NA
NA
79 ⫾ 2.34
40.68 ⫾ 2.18
⬃148.1

SIc
NA
NA
NA
NA
NA
131.6
107.05
617.08

aEC

median effective concentration. Measure of antiparasitic activity against L. major promastigotes.
median cytotoxic concentration. Measure of cytotoxicity in mammalian cells (intraperitoneal mouse
macrophages [IP⌽]).
cSI, selectivity index (CC /EC ).
50
50
dNA, not applicable.

RESULTS
MetAP1Lm inhibitors have potent antileishmanial activities and nontoxic effects in intraperitoneal murine macrophages. The efﬁcacy of theMetAP1 inhibitors
tested in this study has been previously demonstrated against the two MetAP1 proteins
from M. tuberculosis through a high-throughput screening assay (22, 33). Thus, to
identify new MetAP inhibitors for the potential treatment of CL, we tested eight MetAP1
inhibitors (OJT001, OJT002, OJT003, OJT004, OJT005, OJT006, OJT007, and OJT008)
(Table 1 and Fig. S2A) to determine their effectiveness against the promastigote form
of L. major. First, parasites were incubated with each of the eight inhibitors (OJT001 to
OJT008) for 24 or 48 h. The most potent antileishmanial agents found were OJT006,
OJT007, and OJT008, exhibiting low 50% effective concentrations (EC50) of 780 nM,
500 nM, and 500 nM, respectively, after only 24 h of incubation (Fig. S2C). Interestingly,
after 48 and 72 h of incubation, their antiparasitic effects increased slightly (Table 1 and
Fig. S2B and D). Next, the cytotoxic effects of MetAP1Lm inhibitors (OJT006, OJT007, and
OJT008) were determined by the addition of alamarBlue to intraperitoneal macrophages (IP⌽) after 24 or 48 h of treatment. None of the three inhibitors displayed
cytotoxicity against IP⌽ at concentrations up to 20 M (Table 1 and Fig. S2E and F).
Importantly, complete inhibition of extracellular promastigotes of an L. major strain
expressing ﬁreﬂy luciferase (L. major-luc) was detected at a low concentration of
3.12 M. Therefore, a wide window of selectivity (the selectivity indices [SI] were 131.6,
107.05, and 617.08 for OJT006, OJT007, and OJT008, respectively) between parasite and
mammalian cell was observed (Table 1).
MetAP1Lm inhibitors reduce the proliferation of L. major intracellular amastigotes. The most potent MetAP1Lm inhibitors (OJT006, OJT007, and OJT008) were
chosen to further study their effects against intracellular amastigotes proliferated inside
IP⌽. Since we are interested in the potential antiproliferative properties of these
inhibitors, we ﬁrst incubated L. major-luc-infected BALB/c IP⌽ for 48 h with OJT006,
OJT007, or OJT008 treatment. We observed that at a concentration of 0.312 M,
OJT006, OJT007, and OJT008 were able to inhibit the proliferation of intracellular
amastigotes by approximately 80%, 90%, and 85%, respectively (Fig. 1). Taken together,
these results indicated that OJT006, OJT007, and OJT008 have high antileishmanial
effects in both the extracellular and intracellular forms of the parasite with no cytotoxicity to mammalian cells. Thus, OJT006, OJT007, and OJT008 were further selected
for evaluation in a preclinical in vivo model of CL. The assay Z factor was 0.5, indicating
this is a satisfactory assay.
MetAP1Lm inhibitors act on target. To determine whether our three lead candidates were speciﬁc against MetAP1Lm, we ﬁrst treated 1 ⫻ 106 transgenic promastigotes/ml (LucMetAP1Lm/p1RlHYG, a transgenic parasite that simultaneously expresses
luciferase and overexpresses MetAP1Lm) or wild-type parasites for 96 h with OJT006,
June 2020 Volume 64 Issue 6 e01422-19
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OJT007, or OJT008. As expected, the antileishmanial activity of amphotericin B (reference drug; control) was not altered in the transfected LucMetAP1Lm/p1RlHYG parasites
(Fig. 2B). In contrast, increases of more than 10-fold were observed in the EC50 values
of OJT006, OJT007, and OJT008 when tested against transfected LucMetAP1Lm promastigotes compared to the values for treatment of wild-type L. major-luc (Fig. 2A and
B). These data strongly suggest that OJT006, OJT007, and OJT008 successfully inhibited
MetAP1Lm, acting on target.
Potent in vivo activity of inhibitor OJT008 against L. major infection. The in vivo
activities of MetAP1Lm inhibitors OJT006, OJT007, and OJT008 were characterized in L.
major-luc-infected BALB/c mice. First, we evaluated the oral drug administration of
different formulations by assessing their antiparasitic activities and potential toxicity in
mice. Mice treated with a formulation in 70% deionized (DI) water–30% polyethylene
glycol 400 (PEG 400) showed it to be well tolerated, with no weight loss observed,
maintaining the antiparasitic activity of OJT006, OJT007, or OJT008 (Fig. S3A and B).
Therefore, this formulation was selected for subsequent experiments. Next, BALB/c
mice (n ⫽ 5) were infected, and after 18 days postinfection (dpi), mice were orally
treated at 20 mg/kg of body weight/day with OJT006, OJT007, or OJT008. After 13
consecutive days of treatment, inhibitors OJT006 and OJT007 were shown to have
lower efﬁcacies than OJT008. However, all showed decreases in the lesion sizes in
treated mice compared to the effect of the placebo control (Fig. S4). Nevertheless, small
lesion sizes were observed through the course of the infection in OJT008-treated mice
(Fig. S4). To further study and corroborate the efﬁcacy of OJT008 in the preclinical

FIG 2 Action of MetAP1Lm inhibitors OJT006, OJT007, and OJT008 is on target. (A) Data from viability assay of L.
major-luc promastigotes (wild type) treated with inhibitor OJT006, OJT007, or OJT008 for 96 h in a concentration
range of 0.13 M to 3.12 M are shown. (B) Data from viability assay of transfected (LucMetAP1Lm/p1RlHYG) L. major
promastigotes treated with the OJT006, OJT007, or OJT008 inhibitors in a concentration range of 0.13 M to
3.12 M for 96 h are shown. Controls were treated with 1% DMSO (diluent drug control) or amphotericin B (Amp
B) at 5 M (reference drug). Error bars indicate SEM.
June 2020 Volume 64 Issue 6 e01422-19
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FIG 1 MetAP1Lm inhibitors OJT006, OJT007, and OJT008 reduced the intracellular proliferation of L. major
amastigotes. Data from high-content imaging assay (HCIA) analysis of intraperitoneal mouse macrophages (IP⌽) infected with L. major-luc metacyclic promastigotes and treated with OJT006, OJT007, or
OJT008 inhibitor from 0.312 M to 20 M for 48 h are shown. Controls were treated with 1% DMSO (drug
diluent control) or amphotericin B (Amp B) at 5 M (reference drug; positive control). Data are represented as the percentages (%) of infected IP⌽ with 5 or more amastigotes per cell. Error bars indicate
standard errors of the means (SEM).

Antimicrobial Agents and Chemotherapy

FIG 3 Oral treatment with OJT008 signiﬁcantly reduced the parasitic burden caused by L. major infection. (A) Quantiﬁcation of parasite bioluminescence emitted in BALB/c mouse footpads infected with L. major-luc metacyclic promastigotes
and treated with 20 mg/kg/day of OJT008, 4 mg/kg/day of amphotericin B (Amp B; reference drug group), or placebo (PBS;
control group). Two-way ANOVA with Dunnett’s multiple-comparison test (compared to placebo group). *, P ⬍ 0.05; **,
P ⬍ 0.01; ***, P ⬍ 0.0001. Error bars indicate SEM. (B) Representative images of in vivo bioluminescence acquired at 1, 18,
25, and 31 dpi from L. major-luc-infected BALB/c mice treated with OJT008, Amp B, or placebo. (C) Quantiﬁcation of
parasitic load (parasite equivalents/100 ng) by qPCR at experimental endpoint (31 dpi). One-way ANOVA (compared to
placebo; control group). **, P ⬍ 0.01. Error bars indicate SEM.

model, we decided to follow the infection during the course of treatment, using in vivo
bioluminescence imaging. Thus, BALB/c mice (n ⫽ 5) were infected and treated using
the same conditions as before, and images were acquired at 18, 25, and 31 dpi (Fig. 3A
and B). Similarly to the results for amphotericin B (reference drug), OJT008 signiﬁcantly
(P ⬍ 0.0001) decreased the parasite’s bioluminescence signal (Fig. 3A and B). Furthermore, quantitative PCR (qPCR) was performed to analyze the parasite burden of mice
treated with OJT008. As expected, compared to the parasite loads in the placebo group,
OJT008-treated mice had a signiﬁcant (P ⬍ 0.01) reduction in parasite load, by 86% (Fig.
3B). Taken together, these ﬁndings suggest that OJT008 successfully reduced and
controlled L. major infection in a preclinical murine model of CL, representing the
therapeutic potential of the inhibitor.
The OJT008 inhibitor is nontoxic in a murine model of CL. Elevated serum levels
of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes are
recognized as markers for cardiac and hepatic damage, respectively (34). As observed
in the experiments whose results are shown in Fig. 4A and B, serum AST and ALT levels
of mice treated with OJT008 were not elevated and were similar to those in the placebo
group, indicative of drug safety. These results were further supported by the observation that the mouse weights in the OJT008-treated group were not statistically different
from the weights in the placebo-treated control group (Fig. 4C). Additionally, OJT008
caused no changes in the behavior, appetite, waste elimination, appearance, or survival
of treated mice compared to these parameters in placebo- and amphotericin B-treated
animals (Fig. 4C). These results demonstrate the oral safety of the MetAP1Lm inhibitor
OJT008 in a preclinical murine model of CL.
DISCUSSION
Despite the advances in understanding the protozoan parasite L. major, CL continues to cause signiﬁcant morbidity. The drugs available to treat this disease (i.e.,
June 2020 Volume 64 Issue 6 e01422-19
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pentavalent antimonials and amphotericin B) are aged, limited in efﬁcacy, and present
severe side effects, and drug resistance continues to be reported. Consequently, there
is an urgent need for new chemotherapeutic approaches to treat CL (35). Herein, we
present data that demonstrate the potential success of novel MetAP1 inhibitors as
chemotherapeutic agents against L. major infection. MetAP1 is a metalloprotease that
removes the N-terminal methionine from proteins and peptides, a process involved in
the highly conserved N-terminal methionine excision (NME) pathway (17). Since NME is
an essential process in both prokaryotes and eukaryotes (19, 36), inhibitors of MetAP
have been suggested as novel chemotherapeutic agents against different forms of
cancer and bacterial, fungal, and parasitic infections (22, 24–29, 33, 37). Moreover, it has
been reported that deletion of MetAP1 in yeast and other eukaryotic cells is detrimental
and leads to cell death (32, 38, 39). Nonetheless, despite the obvious importance of this
metalloprotease in L. major, insufﬁcient effort has been taken in exploiting MetAP1 as
a drug target for CL.
A screening of 175,000 diverse small molecules conducted by Olaleye et al. (22) led
to the discovery of eight potent MetAP1 inhibitors (OJT001 to OJT008). The eight
MetAP inhibitors tested belong to four structurally diverse classes of small-molecule
compounds afﬁliated with four structurally distinct chemical classes. Compounds
OJT001 to OJT005 are ﬁve analogues belonging to the 8-hydroxyquinoline chemical
class and are structurally related analogues with the same pharmacophore (26), while
compounds OJT006, OJT007, and OJT008 are all structurally different, with diverse
pharmacophore classes. OJT006 is a pyridoxal isonicotinoyl compound, OJT007 has the
hydrazine-1-ylidene-containing pharmacophore, and OJT008 has the pyrimidin-4amine pharmacore (Table 2). Treatment of L. major promastigotes and intracellular
amastigotes with inhibitors OJT001 to OJT008 revealed three potent MetAP1Lm inhibitors, OJT006, OJT007, and OJT008, with EC50s in the low range of 0.243 M to
0.640 M. Interestingly, although the ﬁrst ﬁve hydroxyquinoline compounds (OJT001 to
OJT005), with similar pharmacophores, have been reported to have potent activity
against M. tuberculosis MetAP1 and/or antimycobacterial activity (26), they were not
potent against L. major promastigotes, while compounds OJT006, OJT007, and OJT008,
with three different novel pharmacophores, showed potent activity against L. major
promastigotes. These observations suggest the enzyme speciﬁcity and selective toxicity
of the MetAP inhibitors.
In addition, we have demonstrated that the antiparasitic activity observed for the
inhibitors is due to a speciﬁc on-target effect by overexpressing MetAP1. We observed
a 10-fold increase in resistance to the antiparasitic activity of the compounds compared
to the drug resistance of wild-type L. major-luc. Therefore, we can conclude that since
June 2020 Volume 64 Issue 6 e01422-19
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FIG 4 OJT008 is nontoxic in vivo. (A and B) Evaluation of systemic toxicity by serum levels of alanine aminotransferase (ALT) (A) and aspartate
aminotransferase (AST) (B) in L. major-luc-infected BALB/c mice dosed with 20 mg/kg/day of OJT008, 4 mg/kg/day of Amp B, or placebo (PBS).
Pooled serum samples were collected at 31 dpi (endpoint). Positive control [C (⫹)] was provided by the kit’s manufacturer (Sigma-Aldrich). Data
are represented as units/ml (U/ml). Ordinary one-way ANOVA with Dunnett’s multiple-comparison test (compared to positive control). *, P ⬍ 0.05;
**, P ⬍ 0.01; ***, P ⬍ 0.001; ****, P ⬍ 0.0001. (C) Assessment of treatment toxicity by weight change (grams) in L. major-luc-infected BALB/c mice
treated with 20 mg/kg/day of OJT008, Amp B, or placebo (PBS). Two-way ANOVA with Dunnett’s multiple-comparison test (compared to PBS
group). *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001; ****, P ⬍ 0.0001. Error bars indicate SEM.
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TABLE 2 Structural classes of methionine aminopeptidase inhibitors
MetAP inhibitor class
I. 8-Hydroxyquinolines

Core structure

II. Pyridoxal isonicotinoyls

III. Hydrazin-1-ylidenes

there is an excess of MetAP1 enzyme on the transgenic parasites, a higher concentration of the drugs is required to achieve a similar antiparasitic effect. Similarly, these
effects were previously described in an M. tuberculosis model by Olaleye et al. (22).
These data provide evidence that the OJT006, OJT007, and OJT008 compounds speciﬁcally inhibit MetAP1 from L. major.
Drug accessibility and parenteral administration are two of the main reasons for
treatment interruption for leishmaniasis (13, 14). Several reports show that patients
with conditions ranging from cancer to autoimmune and infectious diseases have an
inclination toward oral chemotherapy administration rather than intravenous administration (40–42). Here, we present evidence of potent oral efﬁcacy of MetAP1 inhibitor
OJT008 in a preclinical mouse model of CL. OJT008 signiﬁcantly decreased the parasite
load, by 86%, as shown by bioluminescence assay and qPCR. More importantly, OJT008
did not generate adverse or toxic effects in treated infected BALB/c mice, as observed
by the low systemic levels of AST and ALT that were measured. Furthermore, these data
correlated with no signiﬁcant weight loss and no behavior changes during the course
of treatment. Given these ﬁndings, we propose the MetAP1Lm inhibitor OJT008 for
further preclinical studies as a novel chemotherapy agent, representing an excellent
candidate for the oral treatment of CL.
To summarize, in the present study, we identiﬁed and characterized MetAP1Lm as a
target for the development of novel antileishmanial drugs. We have discovered three
(OJT006, OJT007, and OJT008) novel small-molecule inhibitors of MetAP1Lm with
diverse pharmacophores for potential development of agents for CL treatment. This
is the ﬁrst report of a new pharmacophore targeting L. major-speciﬁc MetAP1
(MetAP1Lm), in inhibitor OJT008, with signiﬁcant antileishmanial activity in vitro and in
vivo. Further delivery experiments are planned, seeking to improve the antileishmanial
activity of OJT008. Our discovery of three new pharmacophores as potent MetAP1Lm
inhibitors makes these pharmacophores and the MetAP1Lm target an attractive combination for further optimization. In addition, structure-activity relationships and X-ray
June 2020 Volume 64 Issue 6 e01422-19
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crystallography structure studies will accelerate the rational design and synthesis of
more potent MetAP1Lm inhibitors. Furthermore, these inhibitors could be used as
chemical probes or tools in the future to better understand the physiologic relevance
of MetAP1Lm in N-terminal methionine excision, as well as the essentiality and substrate
speciﬁcity of this class of enzymes in L. major.

Animals and ethics statement. BALB/c mice aged 6 to 8 weeks were bred and maintained in a
pathogen-free animal biosafety level 2 (ABSL-2) facility at the Laboratory Animal Resources Center (LARC)
at The University of Texas at El Paso (UTEP). All animal studies and procedures were performed so as to
minimize the distress and pain for the animals in accordance with the NIH guidance and animal protocol
A-201107-1, approved by UTEP’s Institutional Animal Care and Use Committee (IACUC).
Culture of Leishmania major. L. major-luc Friedlin clone V1 promastigotes expressing ﬁreﬂy luciferase Lmj-FV1-LUC-TK (L. major strain Friedlin [MHOM/JL/80/Friedlin]) were cultured at 28°C in M199
medium (Sigma-Aldrich) supplemented with hemin, 10% heat-inactivated fetal bovine serum (iFBS;
Gibco), 1% 10,000 U/ml penicillin, 10 mg/ml streptomycin (Gibco) and treated with 50 ng/ml of streptothricin neosulfate (GoldBio) for maintenance of the luciferase (luc) gene.
Culture of mammalian cells. Starch-induced intraperitoneal BALB/c mouse macrophages (IP⌽) were
obtained as described previously (43) and cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Thermo Fisher Scientiﬁc) supplemented with 10% iFBS (Gibco), 1% 10,000 U/ml penicillin, and 10 mg/ml
streptomycin (Gibco).
MetAP1Lm inhibitor formulations. The MetAP1Lm inhibitors were synthesized and three oral
formulations were developed by the Olaleye group at Texas Southern University, Houston, TX. However,
two of the oral formulations were toxic for the in vivo experiments: formulation one, which consisted of
23% PEG-400, 75% glycerin, 0.05% cremophor EL (all from Sigma-Aldrich), and 0.5% Labrasol (Gattefosse),
and formulation two, which consisted of 33.3% capryol 90 (Sigma-Aldrich), 33.3% cremophor EL, and
33.3% Labrasol. Therefore, for in vivo experiments, inhibitors OJT006, OJT007, and OJT008 were dissolved
in a nontoxic oral formulation of 70% deionized (DI) water and 30% PEG-400. Stock solutions were
dissolved in pure dimethyl sulfoxide (DMSO) at a concentration of 1 mM for in vitro studies.
Luciferase viability assay. MetAP1Lm inhibitors OJT001, OJT002, OJT003, OJT004, OJT005, OJT006,
OJT007, and OJT008 were screened against L. major-luc promastigotes. First, parasites at 1 ⫻ 106/ml were
added to 96-well, white, ﬂat-bottom Nunc plates (Thermo Fisher Scientiﬁc) together with the inhibitors
in a ﬁnal concentration range from 0.78 M to 100 M, in triplicates, followed by 96 h of incubation at
28°C. Amphotericin B (Sigma-Aldrich) was used at 5 M as the drug of reference. The efﬁcacies of OJT006,
OJT007, and OJT008 were further evaluated. The efﬁcacies of the compounds were assessed by
monitoring parasite survival by luciferase activity. The substrate 5=-ﬂuoroluciferin (ONE-Glo luciferase
assay system; Promega) was added according to the manufacturer’s protocol, and the signal read in a
luminometer (Luminoskan; Thermo Fisher Scientiﬁc).
alamarBlue assay of mammalian cell cytotoxicity. The cytotoxicity of OJT006, OJT007, and OJT008
was evaluated using BALB/c mouse IP⌽. First, IP⌽ were harvested and seeded at a density of 1 ⫻ 106/ml,
followed by 8 h of incubation. Next, cells were washed, compounds added at an initial concentration of
1 mM, and cells serially diluted and incubated for an additional 24 or 48 h at 37°C, 5% CO2. The
cytotoxicity of the compounds was determined by the addition of alamarBlue (Invitrogen) following the
manufacturer’s recommendations. Plates were read using a ﬂuorometer (Flouroskan; Thermo Fisher
Scientiﬁc). The drugs were tested in triplicates, and three independent experiments were performed.
In vitro evaluation of MetAP1Lm inhibitors by high-content imaging assay. Intraperitoneal mouse
macrophages were seeded in a BD Falcon 96-well, clear-bottom, black imaging plate and infected with
L. major-luc metacyclic promastigotes (44) in a ratio of 10 parasites per macrophage, followed by 24 h of
incubation at 37°C, 5% CO2. The cells were then washed twice and treated for 48 h with MetAP1Lm
inhibitors (OJT006, OJT007, and OJT008). Each drug was tested in triplicate. To determine the quality of
the assay, 10 replicates of each control, 1% DMSO and amphotericin B, were carried out to calculate the
Z factor. Three independent experiments were performed. The procedure was performed as previously
described (45). BD Pathway Bioimager 855 was used to determine the percentage of infected cells
containing at least 5 intracellular parasites.
Homologous overexpression of MetAP1Lm. The MetAP1Lm gene was ampliﬁed from L. major
genomic DNA using the oligonucleotides MetAP1Lm-XbaI sense (5=-TCTAGAGGATCCATGCCCTGCGAAG
GCTGCGGC-3=) and MetAP1Lm-XbaI antisense (5=-TCTAGAGAATTCTCAGATTTTGATTTCGCTGGGGTCTTCG
G-3=). PCR was performed using PCR master mix (Promega), 420 ng of L. major genomic DNA, and
MetAP1Lm sense and antisense primers under conditions of denaturation of 5 min at 95°C, followed by
40 cycles of 60 s at 95°C, 60 s at 68°C, and 90 s at 72°C, and a ﬁnal 5-min elongation period at 72°C. The
PCR product was puriﬁed using the Wizard SV gel and PCR clean-up system (Promega). The ampliﬁed
MetAP1Lm gene was then cloned into the XbaI restriction site of the Leishmania expression vector
p1RlHYG. The plR1HYG expression vector was kindly provided by Stephen M. Beverley at Washington
University, St. Louis, MO. The identiﬁcation of the clone MetAP1Lm/p1RlHYG was conﬁrmed by DNA
sequencing (DNA Analysis Core Facility, Border Biomedical Research Center, El Paso, TX). L. major-luc
promastigotes were transfected with 25 g of MetAP1Lm/p1RlHYG. The transfected (LucMetAP1Lm/
p1RlHYG) parasites were plated in M199 medium, 0.0005% hemin, 10% iFBS (Gibco), 50 ng/ml
streptothricin (GoldBio), 1% agarose, and incubated at 28°C. After 10 days, parasite colonies were
observed, and an individual colony (clone of parasites) was grown in liquid medium supplemented
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with 16 g/ml hygromycin. L. major LucMetAP1Lm/p1RlHYG transgenic parasites were used to conﬁrm
that the activity of MetAP1Lm inhibitors (OJT006, OJT007, and OJT008) was on target by a luciferase
viability assay.
Luciferase assay of Leishmania major overexpressing MetAP1Lm. The inhibitors OJT006, OJT007,
and OJT008 were screened in parallel with 1 ⫻ 106/ml L. major LucMetAP1Lm/p1RlHYG or wild-type
L. major-luc promastigotes for 96 h at 28°C. The assay was performed using the same conditions
described above for the luciferase viability assay.
In vivo antiparasitic activity of MetAP1Lm inhibitors. Male BALB/c mice (6 to 8 weeks old) were
injected in the left hind footpad with 50 l of L. major-luc metacyclic promastigotes in DMEM (1 ⫻ 106/
ml) after puriﬁcation by Ficoll step gradient as previously described (44). After 18 days postinfection (dpi),
animals were treated orally with 20 mg/kg/day (100 l/day) of OJT006, OJT007, or OJT008 or 4 mg/kg/
day intraperitoneally of reference drug amphotericin B (Sigma-Aldrich) for a total of 13 days (n ⫽ 5 mice
per group). Infection was monitored by footpad lesion measurements using a digital caliper or by
bioluminescence imaging in an IVIS Lumina III in vivo imaging system (Perkin Elmer). Bioluminescence
images were acquired at 18, 25, and 31 dpi after administration of 200 l of 150 mg kg⫺1 D-luciferin in
phosphate-buffered saline (PBS; Gold Biotechnology) as previously described (46). After D-luciferin
injection, mice were kept conscious for 10 min to allow luciferin to be metabolized and circulate and
then anesthetized with 2.5% gaseous isoﬂurane and imaged after 5 additional minutes. Luminescence data were analyzed using Living Image software (Perkin Elmer). Quantiﬁcation of bioluminescence per footpad is represented as radiance (photons per second per square centimeter per
steradian [p/s/cm2/sr]).
Parasite load by quantitative PCR. At the experimental endpoint, mice were euthanized by CO2
overdose and the infected footpads were harvested from all groups. Genomic DNA was extracted from
20 to 30 mg of tissue using the high pure PCR template preparation kit (Roche), following the
manufacture’s protocol. Parasite footpad burden was determined by absolute quantiﬁcation based on a
standard DNA curve ranging from 0.5 to 105 L. major parasite equivalents/ml. A standard curve was
produced by extracting DNA from a 20- to 30-mg tissue fragment spiked with 105 L. major promastigotes.
Ampliﬁcation of a 120-bp fragment from kinetoplastic DNA was performed using 100 nM forward primer
(5=-CTTTTCTGGTCCTCCGGGTAGG-3), 100 nM reverse primer (5=-CCACCCGGCCCTATTTTACACCAA-3=),
and TaqMan probe (5=-FAM-TTTCGCAGAACGCCCCTACCCGC-TAMRA-3=) (47). As an internal control, a
linearized pUC57 plasmid containing a sequence from Arabidopsis thaliana was spiked before all DNA
extractions as previously described (48). TaqMan chemistry allowed a 2-step temperature cycle. PCR
conditions were set at 50°C for 2 min, 94°C for 10 min, followed by 45 cycles at 94°C for 15 s and 55°C
for 1 min (47). Samples were run in triplicate in the StepOnePlus real-time PCR System (Applied
Biosystems), and parasite equivalents per 100 ng were plotted. All the conditions were followed as
previously described (49).
Toxicity monitoring and assessment. Treatment toxicity was evaluated by monitoring mouse
weight changes periodically. Weight changes (grams) were normalized by subtracting from the mouse’s
initial weight. Moreover, blood was collected by cardiac puncture at the endpoint and serum obtained
by centrifugation at 2,000 rpm for 10 min. The levels of serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) enzymes in OJT008-treated mice were measured according to the
manufacturer’s recommendations (ALT or AST activity kit; Sigma-Aldrich).
Statistical analysis. All data were analyzed and plotted using GraphPad Prism 7.0 (GraphPad
Software, Inc., La Jolla, CA). The median lethal dosage (LD50), half-maximal cytotoxic concentration (CC50),
and half-maximal effective concentration (EC50) were calculated. Ordinary one-way analysis of variance
(ANOVA) or two-way ANOVA was employed in the statistical analysis. Values were considered signiﬁcant
when P was ⬍0.05.
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